Prevalence of Mood and Anxiety Disorders in Adult Patients With Pulmonary Langerhans Cell Histiocytosis
- Conditions
- Pulmonary Langerhans Cell Histiocytosis
- Interventions
- Other: Evaluation of co-morbid psychiatric disorders
- Registration Number
- NCT05114304
- Lead Sponsor
- Assistance Publique - Hôpitaux de Paris
- Brief Summary
Pulmonary Langerhans cell histiocytosis (PLCH) is a rare disease, of unknown etiology, that occurs almost exclusively in smokers.The clinical experience suggests a high prevalence of anxiety symptoms and an addictive profile. However, no study to date has precisely investigated the prevalence of co-morbid psychiatric disorders in this population.The aim of the study is to evaluate the prevalence of co-morbid psychiatric disorders in adult PLCH patients.
This study should allow:
* to assess the prevalence of psychiatric disorders co-morbid in PLCH patients
* a targeted and more effective management of patients
* a better response rate to smoking and cannabis weaning, that represents a major goal for these patients.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 100
- Patients of 18 years of age or older with PLCH diagnosed at adulthood
- Patients affiliated to the French Health Care System
- Informed patients
- Patient unable to understand the interview (language barrier)
- Patient under guardianship or curatorship
- Patient under AME (French medical help for foreigners)
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Pulmonary Langerhans cell histiocytosis (PLCH) Evaluation of co-morbid psychiatric disorders Adults with pulmonary Langerhans cell histiocytosis
- Primary Outcome Measures
Name Time Method Proportion of patients with at least one of the disorders detailed in the Mini International Neuropsychiatric Interview (MINI) test at inclusion The Mini-International Neuropsychiatric Interview (M.I.N.I.) is a structured diagnostic interview (40 minutes duration), exploring in a standardized way the main psychiatric disorders of Axis I of the DSM-IV TR (American Psychiatric Association), namely 14 items with a binary result for each specified disorder
- Secondary Outcome Measures
Name Time Method Number of previous tobacco weaning episodes and co-morbid psychiatric disorders at inclusion Proportion of patients with active tobacco consumption with or without comorbid psychiatric disorder at inclusion Tobacco consumption will be assessed by Fagerström survey and DSM-5, cotinine in urine quantification and expired carbon monoxide for patients using nicotine substitutes. Fargerstrom test evaluates the dependence on cigarettes from 0 to 10 (0 indicated a very low dependence and 10 a very strong dependence)
Proportion of patients with persistent tobacco consumption despite nicotine replacement treatment at inclusion Tobacco consumption will be assessed by Fagerström survey and DSM-5 and expired carbon monoxide for patients with nicotine substitutes
Proportion of patients with at least one comorbid addictive disorder among: tobacco, alcohol, cannabis, benzodiazepines, cocaine, opiates at inclusion Definition and diagnosis of addictive disorder will be assessed with Diagnostic and Statistical Manual of Mental Disorders-5 (DSM-5)
Number of co-morbid psychiatric disorders at inclusion Factors associated with psychiatric disorders as assessed by Mini International Neuropsychiatric Interview (MINI) test at inclusion The Mini-International Neuropsychiatric Interview (M.I.N.I.) is a structured diagnostic interview (40 minutes duration), exploring in a standardized way the main psychiatric disorders of Axis I of the DSM-IV TR (American Psychiatric Association), namely 14 items with a binary result for each specified disorder
Trial Locations
- Locations (1)
Hôpital Saint-Louis, Centre de référence national des histiocytoses, Service de Pneumologie
🇫🇷Paris, France